Tag: Abiraterone acetate

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By
Prof. Gerhardt Attard, UCL Cancer Institute London, UK
Trial
Phase 3, STAMPEDE
Conference
ESMO 2022
Type
Peer-reviewed article

17 November 2022 00:23

Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer

Presented By
Dr Rahul Aggarwal, University of California San Francisco, CA, USA
Trial
Phase 3, PRESTO
Conference
ESMO 2022
Type
Peer-reviewed article

17 November 2022 00:13

PROpel: Good results for abiraterone plus olaparib in mCRPC

Presented By
Prof. Noel Clarke, University of Manchester, UK
Trial
Phase 3, PROpel
Conference
EAU 2022
Type
News article

22 July 2022 12:37

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By
Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada
Trial
Phase 2, ACDC-RP
Conference
ASCO GU 2022
Type
Peer-reviewed article

8 April 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By
Dr Guilhem Roubaud, Institut Bergonié, France
Trial
Phase 3, PEACE-1
Conference
ASCO GU 2022
Type
Peer-reviewed article

8 April 2022 11:21

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial
Phase 3, PEACE-1, STAMPEDE, ARCHES
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:27

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By
Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France
Trial
Phase 3, PEACE-1
Conference
EAU 2021
Type
Peer-reviewed article

31 August 2021 12:15

Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC

Presented By
Dr Karim Fizazi , Institut Gustav Roussy, France
Trial
Phase 3, PEACE-1
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 22:19

Apalutamide prolongs progression-free survival in prostate cancer

Presented By
Dr Dana Rathkopf, Memorial Sloan Kettering Cancer Center, New York, USA
Trial
Phase 3, ACIS
Conference
ASCO GU 2021
Type
Peer-reviewed article

24 March 2021 14:49

Abiraterone in M1 hormone-naïve prostate cancer

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 14:51

New treatment option for patients with mCRPC

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 14:50
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com